United States (Change Country)PD173074 Chemical Structure
PD173074 is a potent ATP-competitive, reversible FGFR and VEGFR inhibitor with IC50 of 5, 21.5 and ~100 nM for FGFR3, FGFR1 and VEGFR2, respectively.PD173074 is a cell-permeable pyridopyrimidine compound. PD 173074 arrests the G0/G1 phase of FGFR3-expressing cells. PD173074 inhibits PDGFR and c-Src only at much higher concentration (IC50 = 17.6 µM, 19.8 µM, respectively) and exhibits little effect against EGFR, InsR, MEK, and cPKC even at concentrations as high as 50 µM. Shown to inhibit the autophosphorylation of endogenous FGFR1 (IC50 <5 nM) and overexpressed VEGFR2 (IC50 <200 nM) in NIH3T3 cells in vitro, and FGF- and VEGF-induced angiogenesis in mice in vivo. [1][2]
[1] Cancer Res 2008;68:6902-6907
[2] Journal of Neuroscience Research 2003;74:486–493
| Molecular Weight (WM): | 523.67 |
|---|---|
| Formula: | C28H41N7O3 |
| Solubility(R.T.:25°C): | DMSO 105mg/mL |
| Water <1mg/mL | |
| Ethanol 105mg/mL |
A collection of 715 inhibitors
A collection of 271 kinase inhibitors
A collection of 785 FDA approved drugs
A collection of 144 natural products
A collection of 84 chemotherapeutic agents
A collection of 1463 bioactive compounds
A collection of 117 tyrosine kinase inhibitors
Data from [SCIENCE 2011;331, 912-916] PD173074 purchased from Selleck
;Molecular & Cellular Proteomics , 2012 PD173074 purchased from Selleck
Keywords:buy PD173074 | PD173074 supplier | purchase PD173074 | PD173074 cost | PD173074 manufacturer | order PD173074 | PD173074 distributor